Without a specific news headline driving the move, DexCom (DXCM) sits at a recent close of US$70.69, leaving investors weighing its continuous glucose monitoring business against recent share price ...

DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins, leading me to lower my rating from buy to hold. Despite demographic tailwinds and a growing market, ...

In the preceding three months, 12 analysts have released ratings for DexCom (NASDAQ:DXCM), presenting a wide array of ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

DexCom (NASDAQ:DXCM) stock experienced a significant 16% surge on Friday following its Q1 earnings release and a share buyback announcement. The company’s first-quarter sales reached $1.04 billion, ...

DexCom (NASDAQ:DXCM) stock saw a notable increase of 16% on Friday following the announcement of its Q1 earnings and a share buyback program. The company’s first-quarter sales hit $1.04 billion, ...

We recently published an article titled 13 Best Internet of Things (IoT) Stocks to Buy Now. On February 13, Mizuho analyst Anthony Petrone raised the price target on DexCom, Inc. (NASDAQ:DXCM) to $90 ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A strong fourth-quarter 2024 performance and a series of favorable coverage decisions are ...

Predictions of a sales-growth slowdown sent DexCom stock tumbling this summer. Management predicted third-quarter sales would rise by just 1% to 3% year over year. Two of DexCom's top competitors ...

Let's consider why this healthcare specialist could be an under-the-radar winner of the GLP-1 boom. Will AI create the world's first trillionaire? Our team just released a report on the one ...